6,904 reports of this reaction
4.0% of all MEPOLIZUMAB reports
#3 most reported adverse reaction
WHEEZING is the #3 most commonly reported adverse reaction for MEPOLIZUMAB, manufactured by GlaxoSmithKline LLC. There are 6,904 FDA adverse event reports linking MEPOLIZUMAB to WHEEZING. This represents approximately 4.0% of all 173,706 adverse event reports for this drug.
Patients taking MEPOLIZUMAB who experience wheezing should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WHEEZING is moderately reported among MEPOLIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to wheezing, the following adverse reactions have been reported for MEPOLIZUMAB:
The following drugs have also been linked to wheezing in FDA adverse event reports:
WHEEZING has been reported as an adverse event in 6,904 FDA reports for MEPOLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
WHEEZING accounts for approximately 4.0% of all adverse event reports for MEPOLIZUMAB, making it one of the most commonly reported side effect.
If you experience wheezing while taking MEPOLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.